There is a changing dynamic in vaccine technology transfer, with joint
ventures, acquisitions and establishment by multinational manufacturers
of subsidiaries in developing countries becoming more frequent. The establishment of research-based entities developing and providing new
vaccines may also squeeze existing generic manufacturers out of the
market. The latter will need to invest in R&D to remain competitive.